Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward C Keystone

Showing results (101-110 of 159) with videos related to

Pageof 16
Sort By:
The Journal of Rheumatology|January 17, 2019
MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid ArthritisCharles Peterfy, Julie DiCarlo, Paul Emery, et al.
Annals of the Rheumatic Diseases|November 9, 2012
Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patientsRonald F van Vollenhoven, Paul Emery, Clifton O Bingham, et al.
The Journal of Rheumatology|October 3, 2014
Prognosis of seronegative patients in a large prospective cohort of patients with early inflammatory arthritisLillian Barra, Janet E Pope, John E Orav, et al.
The Journal of Rheumatology|October 3, 2012
Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX studyEdward C Keystone, Stanley B Cohen, Paul Emery, et al.
Rheumatology (Oxford, England)|May 19, 2012
Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trialEdward C Keystone, Bernard Combe, Josef Smolen, et al.
RMD Open|June 9, 2021
Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b/4 methotrexate withdrawal non-inferiority study (ORAL Shift)Stanley B Cohen, Janet Pope, Boulos Haraoui, et al.
The Journal of Rheumatology|December 17, 2015
Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD TrialEdward C Keystone, Mark C Genovese, Stephen Hall, et al.
Arthritis Research & Therapy|August 16, 2020
Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritisJosef S Smolen, Young Mo Kang, Wan-Hee Yoo, et al.
Arthritis and Rheumatism|January 16, 2003
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trialMichael E Weinblatt, Edward C Keystone, Daniel E Furst, et al.
Arthritis Care & Research|October 11, 2014
Effect of age at menopause on disease presentation in early rheumatoid arthritis: results from the Canadian Early Arthritis CohortLauren E Wong, Wei-Ti Huang, Janet E Pope, et al.
Pageof 16

Showing results (101-110 of 159) with videos related to

Sort By:
Pageof 16
The Journal of Rheumatology|January 17, 2019
MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid ArthritisCharles Peterfy, Julie DiCarlo, Paul Emery, et al.
Annals of the Rheumatic Diseases|November 9, 2012
Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patientsRonald F van Vollenhoven, Paul Emery, Clifton O Bingham, et al.
The Journal of Rheumatology|October 3, 2014
Prognosis of seronegative patients in a large prospective cohort of patients with early inflammatory arthritisLillian Barra, Janet E Pope, John E Orav, et al.
The Journal of Rheumatology|October 3, 2012
Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX studyEdward C Keystone, Stanley B Cohen, Paul Emery, et al.
Rheumatology (Oxford, England)|May 19, 2012
Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trialEdward C Keystone, Bernard Combe, Josef Smolen, et al.
RMD Open|June 9, 2021
Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b/4 methotrexate withdrawal non-inferiority study (ORAL Shift)Stanley B Cohen, Janet Pope, Boulos Haraoui, et al.
The Journal of Rheumatology|December 17, 2015
Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD TrialEdward C Keystone, Mark C Genovese, Stephen Hall, et al.
Arthritis Research & Therapy|August 16, 2020
Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritisJosef S Smolen, Young Mo Kang, Wan-Hee Yoo, et al.
Arthritis and Rheumatism|January 16, 2003
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trialMichael E Weinblatt, Edward C Keystone, Daniel E Furst, et al.
Arthritis Care & Research|October 11, 2014
Effect of age at menopause on disease presentation in early rheumatoid arthritis: results from the Canadian Early Arthritis CohortLauren E Wong, Wei-Ti Huang, Janet E Pope, et al.
Pageof 16